Foghorn Therapeutics Inc. (FHTX) community

FHTXNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 11/301% below fair value

$2.07+0.02 (+0.98%)

Close on Nov 13, 2026Market cap $122.93MP/E 29.6Yield –

Community

Notes and questions about Foghorn Therapeutics from other investors

No posts about FHTX yet

Discussion is coming to every stock. Posts will be able to point at any number on these pages, so everyone sees exactly which figure is being discussed.

Where these numbers come from

Parsed from the XBRL in Foghorn Therapeutics's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is FHTX.

Compare: FHTX vs TNGX · FHTX vs FULC · FHTX vs RCUS · FHTX vs PGEN · FHTX vs BCYC

Revenue growth357.3% · median -58.3%

Operating margin2.1% · median -189.4%

Net margin8.4% · median -169.8%

Company	Revenue	Growth
PGEN	$156.94M	–
FHTX	$112.13M	+357.3%
RCUS	$100.00M	-58.3%
BCYC	$83.53M	+194.7%
TNGX	$0	-100.0%
FULC	–	–

Company

Next earnings (est.): Mar 10, 2027, after close
Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 106
Held by institutions: 75.6%
Auditor: Deloitte& Touche LLP
SEC CIK: 1822462

Advertisement
300 × 250

See a number that looks wrong?